Falcon Point Capital LLC Purchases 3,456 Shares of Integra Lifesciences Holdings Corp (IART)

Falcon Point Capital LLC grew its position in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 1.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 258,663 shares of the life sciences company’s stock after buying an additional 3,456 shares during the period. Integra Lifesciences accounts for 2.1% of Falcon Point Capital LLC’s investment portfolio, making the stock its 21st largest position. Falcon Point Capital LLC owned about 0.33% of Integra Lifesciences worth $12,380,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the stock. State Street Corp raised its stake in shares of Integra Lifesciences by 5.2% during the 2nd quarter. State Street Corp now owns 1,575,125 shares of the life sciences company’s stock valued at $85,860,000 after purchasing an additional 78,082 shares during the period. Orbimed Advisors LLC raised its stake in shares of Integra Lifesciences by 155.5% during the 3rd quarter. Orbimed Advisors LLC now owns 1,090,910 shares of the life sciences company’s stock valued at $55,069,000 after purchasing an additional 664,000 shares during the period. Jennison Associates LLC raised its stake in shares of Integra Lifesciences by 48.3% during the 3rd quarter. Jennison Associates LLC now owns 1,034,702 shares of the life sciences company’s stock valued at $52,232,000 after purchasing an additional 336,930 shares during the period. Westfield Capital Management Co. LP raised its stake in shares of Integra Lifesciences by 5.8% during the 3rd quarter. Westfield Capital Management Co. LP now owns 840,556 shares of the life sciences company’s stock valued at $42,431,000 after purchasing an additional 45,840 shares during the period. Finally, Sector Gamma AS raised its stake in shares of Integra Lifesciences by 7.3% during the 3rd quarter. Sector Gamma AS now owns 529,230 shares of the life sciences company’s stock valued at $26,716,000 after purchasing an additional 36,000 shares during the period. Institutional investors own 86.64% of the company’s stock.

IART has been the topic of a number of analyst reports. Zacks Investment Research lowered Integra Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, October 25th. Oppenheimer reiterated a “buy” rating on shares of Integra Lifesciences in a research note on Thursday, October 26th. JPMorgan Chase & Co. lowered Integra Lifesciences from an “overweight” rating to a “neutral” rating and set a $44.00 price objective on the stock. in a research note on Friday, October 27th. TheStreet lowered Integra Lifesciences from a “b” rating to a “c+” rating in a research note on Thursday, October 26th. Finally, Jefferies Group reiterated a “buy” rating and set a $56.00 price objective on shares of Integra Lifesciences in a research note on Sunday, October 29th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $52.70.

Integra Lifesciences Holdings Corp (NASDAQ:IART) opened at $49.99 on Tuesday. The firm has a market capitalization of $3,920.00, a PE ratio of 81.95, a price-to-earnings-growth ratio of 1.58 and a beta of 0.67. The company has a quick ratio of 3.39, a current ratio of 4.49 and a debt-to-equity ratio of 1.26. Integra Lifesciences Holdings Corp has a one year low of $40.51 and a one year high of $56.42.

COPYRIGHT VIOLATION NOTICE: “Falcon Point Capital LLC Purchases 3,456 Shares of Integra Lifesciences Holdings Corp (IART)” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/02/13/falcon-point-capital-llc-purchases-3456-shares-of-integra-lifesciences-holdings-corp-iart.html.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Institutional Ownership by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply